Prevalence, social-demographic and cognitive correlates of depression in Chinese psychiatric medical staff

Hu, Wei; Xiong, Yin; Yin, Xiaolin; Zhu, Zhen; Guan, Lu Yang; Wen, Hongbo; Yin, Guiqin; Jiang, Cai Xia; Xu, Xiang; Gao, Song; Jia, Qiu Fang; Li, Hui

doi:10.1016/j.jad.2019.11.133

Cited by 11 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the systematic review and meta-analysis, Sahebi et al ( 2021 ) reported that the prevalence of depression and anxiety in the healthcare workers during the COVID-19 pandemic was 24.83 and 24.94%, respectively; these percentages are consistent with this study (corresponding 26.7 and 24.1%). However, this study reported higher prevalence rates of depressive (26.7%) and anxious (24.1%) symptoms among Chinese psychiatrists than in the corresponding studies (18.4% depression and 13.3% anxiety) in Chinese medical staff (including 40.6% doctors and 59.4% nurses) during the pandemic (Liu et al, 2021 ) and in Chinese psychiatric medical staff (17.4% depression) before the COVID-19 pandemic (Hu et al, 2020 ). This may relate to sample differences in measurements, professions, and/or regions.…”

Section: Discussionmentioning

confidence: 90%

Depression, Anxiety, Stress, and Their Associations With Quality of Life in a Nationwide Sample of Psychiatrists in China During the COVID-19 Pandemic

Xia

Yang

et al. 2022

Front. Psychol.

View full text Add to dashboard Cite

ObjectivesThe COVID-19 pandemic has negatively affected wellbeing. However, the impact on the mental health status of Chinese psychiatrists and their relationship with quality of life (QOL) has not been examined.MethodsThis was a national cross-sectional survey performed between January 11 and March 15, 2021. Demographic and work-related data were collected anonymously using an online questionnaire. Common mental health symptoms and QOL were assessed using the Depression Anxiety Stress Scale-Chinese version and the World Health Organization Quality of Life Schedule-Brief, respectively.ResultsA total of 3,783 psychiatrists completed this questionnaire. The prevalence of depressive, anxious, and stress symptoms were 26.7% (95%CI = 25.3–28.1%), 24.1% (95%CI = 22.8–25.5%), and 11.6% (95%CI = 10–12%), respectively. Moreover, 11.1% of the participants endorsed both depressive and anxious symptoms, and 8% endorsed symptoms in all three domains. Binary logistic regression showed that aged 30–39 years (OR = 1.5, P = 0.03), male gender (OR = 1.2, P = 0.04), single (OR = 1.44, P = 0.01), and having a negative perception of the COVID-19 on healthcare (OR = 2.34, P <0.001) were factors associated with higher levels of depressive symptoms. Participants who were divorced and widowed (OR = 1.56, P = 0.03), worked more than 4 night shifts/month (OR = 1.33, P<0.001) and/or longer working years (OR = 1.71, P < 0.001), and had a negative perceived impact of the COVID-19 on healthcare (OR = 2.05, P < 0.001) were more inclined to experience anxious symptoms. In addition, psychiatrists with high QOL scores had lower odds of experiencing depressive, anxious, and stress symptoms (all P < 0.001). Multivariate analysis showed that the presence of each of the three types of mental health symptoms was independently associated with lower QOL (all P < 0.05). In addition, the depression × anxious × stress interaction was significantly correlated with lower QOL (P < 0.05).ConclusionApproximately one-fourth of psychiatrists in China experienced depressive and anxious symptoms during the COVID-19 pandemic, and more than one-tenth reported stress. Mental health symptoms were significant contributors to lower QOL. The psychological wellbeing of psychiatrists during the pandemic requires more attention, and interventions are needed to improve the psychological wellbeing and QOL of physicians who care for individuals with mental disorders.

show abstract

Section: Discussionmentioning

confidence: 90%

Depression, Anxiety, Stress, and Their Associations With Quality of Life in a Nationwide Sample of Psychiatrists in China During the COVID-19 Pandemic

Xia

Yang

et al. 2022

Front. Psychol.

View full text Add to dashboard Cite

show abstract

“…13 The cognitive symptoms associated with MDD can also contribute to MDD-related social, functional, and work-related disability. [14][15][16][17][18] Approximately three-quarters of patients with MDD in China present with cognitive impairment, which continues for approximately one-third of patients after 6 months of treatment, 18 resulting in impaired quality of life and productivity, independent of the severity of depressive symptoms. [18][19][20] Therefore, both symptomatic and functional improvement during treatment of MDD are desirable for increasing patients' chances of recovery and restoration.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study

Wang¹,

Xiao²,

Ren³

et al. 2022

NDT

View full text Add to dashboard Cite

Background Major depressive disorder (MDD) affects >163 million people worldwide and is a leading cause of disability in China. Functional impairment occurs alongside cognitive symptoms, anxiety, and depression, reducing quality of life and productivity in patients with MDD. Purpose The multimodal antidepressant vortioxetine has demonstrated efficacy in relieving depressive and functional symptoms of MDD in randomized controlled trials (RCTs). The RELIEVE China study aimed to investigate the real-world effectiveness of vortioxetine in China. Patients and Methods This was an observational, prospective cohort study in patients with MDD initiating treatment with vortioxetine at physician’s discretion in China. Participants were followed up for 24 weeks and assessed at 3 time points: baseline, week 8, and week 24. The primary objective was to assess the change from baseline to weeks 8 and 24 in functional impairment as measured by Sheehan Disability Scale (SDS) total score. Additional assessments included SDS subdomains, measures of depression severity, anxiety, and cognition. The safety and tolerability of vortioxetine were also examined. Results In total, 859 patients were included in the analysis. A consistent and significant improvement in functional impairment was observed during the study, with baseline mean SDS total score (16.7 points) decreasing by 5.42 (SE, 0.22) and 8.71 (SE, 0.226) points at week 8 and week 24, respectively ( P <0.0001). Improvements in other functioning, cognitive, and anxiety assessments were also observed (all P <0.0001). A total of 74.7% of patients had responded, and 63.9% had reached remission at week 24. The tolerability profile of vortioxetine in this real-world population was consistent with the established tolerability profile for this drug. Conclusion This study demonstrated the short- and long-term effectiveness and tolerability of vortioxetine for patients with MDD in a real-world setting in China. These findings are consistent with the efficacy and safety profile observed during RCTs.

show abstract

“…Increasing evidence from previous studies has supported that cognitive impairment is a core feature of MDD and it affects the treatment, rehabilitation, quality life, and even employment for MDD [ 1 – 3 , 7 ]. Thus, mitigating cognitive deficits should be the focus of MDD treatment [ 8 , 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…Cognitive deficits have been regarded as the core features of major depressive disorder (MDD) [ 1 – 3 ]. Previous studies indicated that cognitive deficits of MDD mainly occurred in the following cognitive domains, such as memory, attention, visuospatial/constructional skills, language, executive function and processing speed [ 2 , 4 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

Association between increased serum interleukin-8 levels and improved cognition in major depressive patients with SSRIs

Cai

Zhu

et al. 2023

BMC Psychiatry

Self Cite

View full text Add to dashboard Cite

Background The effect of neuroinflammatory cytokines on cognitive deficits in patients with major depressive disorder (MDD) can be altered by selective serotonin reuptake inhibitors (SSRIs). This study aimed to examine serum interleukin-8 (IL-8) levels, cognitive function, and their associations in MDD patients with SSRIs. Methods Thirty SSRI-treated MDD patients and 101 healthy controls were recruited for this study. We examined cognitive performance using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and serum IL-8 levels using the Human Inflammatory Cytokine Cytometric Bead Array in both cases and controls. Results The RBANS test scores were significantly lower in MDD patients with SSRIs than in healthy controls after controlling for covariates (all p < 0.001). Serum levels of IL-8 were higher in MDD patients with SSRIs than in healthy controls after adjusting for covariates (F = 3.82, p = 0.05). Serum IL-8 levels were positively correlated with sub-scores of delayed memory (r = 0.37, p = 0.04) and visuospatial/constructional (r = 0.43, p = 0.02) in MDD patients with SSRIs but not in in healthy controls (delayed memory score: r = -0.12, p = 0.24; visuospatial/constructional score: r = 0.02, p = 0.81). Conclusions Our findings suggested that increased serum IL-8 level might not only be involved in the MDD psychopathology or the use of SSRIs but also correspond to improving MDD delayed memory and visuospatial/constructional function.

show abstract

Prevalence, social-demographic and cognitive correlates of depression in Chinese psychiatric medical staff

Cited by 11 publications

References 20 publications

Depression, Anxiety, Stress, and Their Associations With Quality of Life in a Nationwide Sample of Psychiatrists in China During the COVID-19 Pandemic

Depression, Anxiety, Stress, and Their Associations With Quality of Life in a Nationwide Sample of Psychiatrists in China During the COVID-19 Pandemic

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study

Association between increased serum interleukin-8 levels and improved cognition in major depressive patients with SSRIs

Contact Info

Product

Resources

About